UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Metformin and risk of age-related macular degeneration in individuals with type 2 diabetes: a retrospective cohort study

Gokhale, Krishna M; Adderley, Nicola J; Subramanian, Anuradhaa; Lee, Wen Hwa; Han, Diana; Coker, Jesse; Braithwaite, Tasanee; ... Nirantharakumar, Krishnarajah; + view all (2022) Metformin and risk of age-related macular degeneration in individuals with type 2 diabetes: a retrospective cohort study. British Journal of Ophthalmology 10.1136/bjophthalmol-2021-319641. (In press). Green open access

[thumbnail of Keane_T2DM metformin and risk of AMD BJO 20220111 clean.pdf]
Preview
Text
Keane_T2DM metformin and risk of AMD BJO 20220111 clean.pdf

Download (370kB) | Preview

Abstract

BACKGROUND: Age-related macular degeneration (AMD) in its late stages is a leading cause of sight loss in developed countries. Some previous studies have suggested that metformin may be associated with a reduced risk of developing AMD, but the evidence is inconclusive. AIMS: To explore the relationship between metformin use and development of AMD among patients with type 2 diabetes in the UK. METHODS: A large, population-based retrospective open cohort study with a time-dependent exposure design was carried out using IQVIA Medical Research Data, 1995-2019. Patients aged ≥40 with diagnosed type 2 diabetes were included.The exposed group was those prescribed metformin (with or without any other antidiabetic medications); the comparator (unexposed) group was those prescribed other antidiabetic medications only. The exposure status was treated as time varying, collected at 3-monthly time intervals.Extended Cox proportional hazards regression was used to calculate the adjusted HRs for development of the outcome, newly diagnosed AMD. RESULTS: A total of 173 689 patients, 57% men, mean (SD) age 62.8 (11.6) years, with incident type 2 diabetes and a record of one or more antidiabetic medications were included in the study. Median follow-up was 4.8 (IQR 2.3-8.3, range 0.5-23.8) years. 3111 (1.8%) patients developed AMD. The adjusted HR for diagnosis of AMD was 1.02 (95% CI 0.92 to 1.12) in patients prescribed metformin (with or without other antidiabetic medications) compared with those prescribed any other antidiabetic medication only. CONCLUSION: We found no evidence that metformin was associated with risk of AMD in primary care patients requiring treatment for type 2 diabetes.

Type: Article
Title: Metformin and risk of age-related macular degeneration in individuals with type 2 diabetes: a retrospective cohort study
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1136/bjophthalmol-2021-319641
Publisher version: http://dx.doi.org/10.1136/bjophthalmol-2021-319641
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: degeneration, epidemiology, macula
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10143945
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item